IPSEN (OTCMKTS:IPSEY) Hits New 12-Month High – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $49.80 and last traded at $49.80, with a volume of 121 shares traded. The stock had previously closed at $47.95.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

IPSEN Stock Performance

The business’s 50-day moving average is $46.75 and its 200-day moving average is $40.51.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).